Similar articles

• Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.

  Piatosa B, Grenda R, Prokurat S. Piatosa B, et al. Transplant Proc. 1993 Aug;25(4):2574. Transplant Proc. 1993. PMID: 8356675 Clinical Trial. No abstract available.
• Cytokine-release syndrome: differences between high and low doses of OKT3.

  Norman DJ, Kimball JA, Barry JM. Norman DJ, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):35-8. Transplant Proc. 1993. PMID: 8465420 Clinical Trial. No abstract available.
• Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.

  Alamartine E, Bellakoul R, Berthoux F. Alamartine E, et al. Transplant Proc. 1994 Feb;26(1):273-4. Transplant Proc. 1994. PMID: 8108975 Clinical Trial. No abstract available.
• A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.

  Stratta RJ, Taylor RJ, Weide LG, Sindhi R, Sudan D, Castaldo P, Cushing KA, Frisbie K, Radio SJ. Stratta RJ, et al. Transplant Proc. 1996 Apr;28(2):917-8. Transplant Proc. 1996. PMID: 8623461 Clinical Trial. No abstract available.
• OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).

  First MR, Schroeder TJ, Hariharan S. First MR, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):25-6. Transplant Proc. 1993. PMID: 8465417 Review. No abstract available.